-
Je něco špatně v tomto záznamu ?
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
VG. Atkinson, P. Quaglino, M. Aglietta, M. Del Vecchio, R. Depenni, F. Consoli, D. Bafaloukos, PF. Ferrucci, S. Tulyte, I. Krajsová, PA. Ascierto, R. Gueli, A. Arance, H. Gogas, H. Banerjee, T. Saliba, E. de Jong, B. Neyns
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
None
Novartis
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
34070224
DOI
10.3390/cancers13102466
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
The dabrafenib plus trametinib (dab + tram) combination has demonstrated durable long-term efficacy in patients with BRAF V600-mutant metastatic melanoma. However, real-world data characterizing patients with long-term benefit are limited. DESCRIBE III was a global, observational, retrospective, chart review study in patients with unresectable or metastatic melanoma treated with dab monotherapy and/or dab + tram combination therapy as part of the Named Patient Program or Individual Patient Program. Overall, 509 patients were enrolled. Patients were categorized into three groups based on their observed treatment duration: long-term (on therapy ≥12 months), intermediate (on therapy ≥6 months and <12 months), and short-term (on therapy <6 months) duration of benefit. More patients in the short-term duration of benefit group had baseline characteristics associated with poor prognosis compared with the other two groups. Median lactate dehydrogenase (LDH) levels (368 U/L) at baseline were also higher in the short-term duration of benefit group. No new safety signals were identified. DESCRIBE III identified baseline characteristics associated with long-term benefit of dab + tram. Lower LDH level and <3 metastatic sites at baseline were associated with a longer duration of benefit, confirming that the findings from COMBI-d and COMBI-v are relevant to patients treated in a real-world setting.
Department of Medical Oncology Candiolo Cancer Institute FPO IRCCS 10060 Candiolo Italy
Department of Medical Oncology Hospital Clinic of Barcelona 08036 Barcelona Spain
Department of Medical Sciences Section of Dermatology University of Turin 10124 Turin Italy
Department of Oncology and Hematology University of Modena and Reggio Emilia 41121 Modena Italy
Department of Oncology University of Torino 10124 Turin Italy
Hematology Oncology and Transfusion Medicine Center Vilnius University 08410 Vilnius Lithuania
Medical Oncology ASST Spedali Civili 25123 Brescia Italy
Medical Oncology Metropolitan Hospital 18547 Athens Greece
Medical Oncology Universitair Ziekenhuis Brussel 1090 Brussels Belgium
Novartis AG 4057 Basel Switzerland
Novartis Pharmaceuticals Corporation East Hanover NJ 07936 USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21017732
- 003
- CZ-PrNML
- 005
- 20210729104012.0
- 007
- ta
- 008
- 210726s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers13102466 $2 doi
- 035 __
- $a (PubMed)34070224
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Atkinson, Victoria G $u Division of Cancer Services, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD 4102, Australia
- 245 12
- $a A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III) / $c VG. Atkinson, P. Quaglino, M. Aglietta, M. Del Vecchio, R. Depenni, F. Consoli, D. Bafaloukos, PF. Ferrucci, S. Tulyte, I. Krajsová, PA. Ascierto, R. Gueli, A. Arance, H. Gogas, H. Banerjee, T. Saliba, E. de Jong, B. Neyns
- 520 9_
- $a The dabrafenib plus trametinib (dab + tram) combination has demonstrated durable long-term efficacy in patients with BRAF V600-mutant metastatic melanoma. However, real-world data characterizing patients with long-term benefit are limited. DESCRIBE III was a global, observational, retrospective, chart review study in patients with unresectable or metastatic melanoma treated with dab monotherapy and/or dab + tram combination therapy as part of the Named Patient Program or Individual Patient Program. Overall, 509 patients were enrolled. Patients were categorized into three groups based on their observed treatment duration: long-term (on therapy ≥12 months), intermediate (on therapy ≥6 months and <12 months), and short-term (on therapy <6 months) duration of benefit. More patients in the short-term duration of benefit group had baseline characteristics associated with poor prognosis compared with the other two groups. Median lactate dehydrogenase (LDH) levels (368 U/L) at baseline were also higher in the short-term duration of benefit group. No new safety signals were identified. DESCRIBE III identified baseline characteristics associated with long-term benefit of dab + tram. Lower LDH level and <3 metastatic sites at baseline were associated with a longer duration of benefit, confirming that the findings from COMBI-d and COMBI-v are relevant to patients treated in a real-world setting.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Quaglino, Pietro $u Department of Medical Sciences, Section of Dermatology, University of Turin, 10124 Turin, Italy
- 700 1_
- $a Aglietta, Massimo $u Department of Oncology, University of Torino, 10124 Turin, Italy $u Department of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo (Torino), Italy
- 700 1_
- $a Del Vecchio, Michele $u Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
- 700 1_
- $a Depenni, Roberta $u Department of Oncology and Hematology, University of Modena and Reggio Emilia, 41121 Modena, Italy
- 700 1_
- $a Consoli, Francesca $u Medical Oncology, ASST Spedali Civili, 25123 Brescia, Italy
- 700 1_
- $a Bafaloukos, Dimitrios $u Medical Oncology, Metropolitan Hospital, 18547 Athens, Greece
- 700 1_
- $a Ferrucci, Pier Francesco $u Tumor Biotherapy Unit, Department of Experimental Oncology, IEO-Istituto Europeo di Oncologia-IRCCS, 20141 Milan, Italy
- 700 1_
- $a Tulyte, Skaiste $u Hematology, Oncology and Transfusion Medicine Center, Vilnius University, 08410 Vilnius, Lithuania
- 700 1_
- $a Krajsová, Ivana $u Department of Dermatovenerology, University Hospital Prague, Charles University, 12808 Prague, Czech Republic
- 700 1_
- $a Ascierto, Paolo A $u Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori-IRCCS "Fondazione G. Pascale", 80131 Naples, Italy
- 700 1_
- $a Gueli, Rossana $u Oncology Unit, ASST Sette Laghi, 21100 Varese, Italy
- 700 1_
- $a Arance, Ana $u Department of Medical Oncology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain
- 700 1_
- $a Gogas, Helen $u Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, 11527 Athens, Greece
- 700 1_
- $a Banerjee, Hiya $u Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
- 700 1_
- $a Saliba, Teddy $u Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
- 700 1_
- $a de Jong, Egbert $u Novartis AG, 4057 Basel, Switzerland
- 700 1_
- $a Neyns, Bart $u Medical Oncology, Universitair Ziekenhuis Brussel, 1090 Brussels, Belgium
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 10 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34070224 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210726 $b ABA008
- 991 __
- $a 20210729104010 $b ABA008
- 999 __
- $a ind $b bmc $g 1676404 $s 1138174
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 10 $e 20210518 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a None $p Novartis
- LZP __
- $a Pubmed-20210726
